Andrew Haydon

Andrew Haydon

UNVERIFIED PROFILE

Are you Andrew Haydon?   Register this Author

Register author
Andrew Haydon

Andrew Haydon

Publications by authors named "Andrew Haydon"

Are you Andrew Haydon?   Register this Author

48Publications

1651Reads

8Profile Views

An update on adjuvant systemic therapies in melanoma.

Melanoma Manag 2019 Nov 13;6(3):MMT28. Epub 2019 Nov 13.

Department of Medical Oncology, The Alfred Hospital, Melbourne 3004, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt-2019-0009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891936PMC
November 2019

Reply to E. Hindié and K.R. Hess.

J Clin Oncol 2019 May 2;37(15):1356-1358. Epub 2019 Apr 2.

Georgina V. Long, MD, PhD, Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Reinhard Dummer, MD, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland; Dirk Schadendorf, MD, PhD, University Hospital Essen, Essen, Germany, and German Cancer Consortium, Heidelberg, Germany; Mario Santinami, MD, Fondazione Istituto Nazionale Tumori, Milan, Italy; Victoria Atkinson, MD, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, and University of Queensland, Brisbane, QLD, Australia; Mario Mandalà, MD, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy; Vanna Chiarion-Sileni, MD, Veneto Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy; James Larkin, MD, PhD, Royal Marsden National Health Service Foundation Trust, London, United Kingdom; Marta Nyakas, MD, Oslo University Hospital, Oslo, Norway; Caroline Dutriaux, MD, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France; Andrew Haydon, MD, PhD, The Alfred Hospital, Melbourne, VIC, Australia; Caroline Robert, MD, PhD, Institute Gustave Roussy, Paris, France; Laurent Mortier, MD, PhD, Université de Lille, Institut National de la Santé et de la Recherche Médicale U 1189, Centre Hospitalier Universitaire Lille, Lille, France; Jacob Schachter, MD, PhD, Sheba Medical Center, Tel HaShomer, Israel, and Tel Aviv University, Tel Aviv, Israel; Thierry Lesimple, MD, MSc, Centre Eugène Marquis, Rennes, France; Ruth Plummer, MD, PhD, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom; Kohinoor Dasgupta, PhD, Novartis Healthcare, Hyderabad, India; Tomas Haas, PhD, Novartis AG, Basel, Switzerland; Mark Shilkrut, MD, PhD and Eduard Gasal, MD, Novartis Pharmaceuticals, East Hanover, NJ; Richard Kefford, MD, PhD, Melanoma Institute Australia, The University of Sydney, Macquarie University, and Westmead Hospital, Sydney, NSW, Australia; John M. Kirkwood, MD, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; and Axel Hauschild, MD, University Hospital Schleswig-Holstein, Kiel, Germany.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.19.00004
Publisher Site
http://dx.doi.org/10.1200/JCO.19.00004DOI Listing
May 2019

High neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy.

Asia Pac J Clin Oncol 2018 Oct 17;14(5):e442-e447. Epub 2018 Jan 17.

Department of Medical Oncology, Alfred Health, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.12846DOI Listing
October 2018

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.

J Clin Oncol 2018 Oct 22:JCO1801219. Epub 2018 Oct 22.

Axel Hauschild, University Hospital Schleswig-Holstein, Kiel; Dirk Schadendorf, University Hospital Essen, Essen; German Cancer Consortium, Heidelberg, Germany; Reinhard Dummer, University Hospital Zürich Skin Cancer Center, Zürich; Tomas Haas, Novartis AG, Basel, Switzerland; Mario Santinami, Fondazione Istituto Nazionale Tumori, Milan; Mario Mandalà, Papa Giovanni XXIII Cancer Center Hospital, Bergamo; Vanna Chiarion-Sileni, Veneto Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Padova, Italy; Victoria Atkinson, Princess Alexandra Hospital; Gallipoli Medical Research Foundation; University of Queensland, Brisbane, Queensland; Andrew Haydon, The Alfred Hospital, Melbourne, Victoria; Richard Kefford, Macquarie University; Westmead Hospital; Richard Kefford and Georgina V. Long, Melanoma Institute Australia; University of Sydney; Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia; James Larkin, Royal Marsden National Health Service Foundation Trust, London; Ruth Plummer, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom; Marta Nyakas, Oslo University Hospital, Oslo, Norway; Caroline Dutriaux, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux; Caroline Robert, Institute Gustave Roussy, Paris; Laurent Mortier, Université de Lille, Institut National de la Santé et de la Recherche Médicale U1189, Centre Hospitalier Universitaire de sa Region Lille, Lille; Thierry Lesimple, Centre Eugène Marquis, Rennes, France; Jacob Schachter, Sheba Medical Center, Tel Hashomer; Tel Aviv University, Tel Aviv, Israel; Kohinoor Dasgupta, Novartis Healthcare, Hyderabad, India; Mark Shilkrut and Eduard Gasal, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and John M. Kirkwood, UPMC Hillman Cancer Center; University of Pittsburgh, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.01219
Publisher Site
http://dx.doi.org/10.1200/JCO.18.01219DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286159PMC
October 2018

Concordance of somatic mutational profile in multiple primary melanomas.

Pigment Cell Melanoma Res 2018 09 15;31(5):592-603. Epub 2018 Apr 15.

Victorian Melanoma Service, Alfred Hospital, Melbourne, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12702DOI Listing
September 2018

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

N Engl J Med 2018 May 15;378(19):1789-1801. Epub 2018 Apr 15.

From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille (J.-J.G.) - all in France; Netherlands Cancer Institute-Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical Center Nijmegen, Nijmegen (R.K.) - all in the Netherlands; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo (M. Mandala), Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione G. Pascale, Naples (P.A.A.), and Universita Degli Studi Di Siena-Policlinico le Scotte, Siena (M. Maio) - all in Italy; Melanoma Institute Australia, the University of Sydney, and Mater and Royal North Shore Hospitals (G.V.L.) and Westmead and Blacktown Hospitals, Melanoma Institute Australia and the University of Sydney (M.S.C.), Sydney, Princess Alexandra Hospital, University of Queensland, Brisbane (V.A.), Alfred Hospital (A.H.) and Peter MacCallum Cancer Centre (S. Sandhu), Melbourne, VIC, and Fiona Stanley Hospital-University of Western Australia-Edith Cowan University Perth, Perth (A.K.) - all in Australia; Cancer Research Center, Moscow (M.L.); Royal Marsden Hospital, London (J.L.); Hospital Clinic Universitari de Barcelona, Barcelona (S.P.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); University Hospital Essen, Essen and German Cancer Consortium, Heidelberg (D.S.), and the Skin Cancer Center, Department of Dermatology, Hannover Medical School, Hannover (R.G.) - all in Germany; Washington University School of Medicine, St. Louis (L.H.-A.); Centre Hospitalier de l'Université de Montréal (CHUM), Centre de Recherche du CHUM, Montreal (R.J.); Christie NHS Foundation Trust, Manchester, United Kingdom (P.L.); Merck, Kenilworth, NJ (N.I.); and the European Organization for the Research and Treatment of Cancer Headquarters, Brussels (S.M., S. Suciu).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1802357DOI Listing
May 2018

Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy.

Br J Cancer 2018 05 14;118(10):1289-1295. Epub 2018 May 14.

Victorian Melanoma Service, Alfred Hospital, Melbourne, VIC, 3004, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0088-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959932PMC
May 2018

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

N Engl J Med 2017 11 10;377(19):1813-1823. Epub 2017 Sep 10.

From the Melanoma Institute Australia, University of Sydney, Royal North Shore and Mater Hospitals (G.V.L.), and Macquarie University, Melanoma Institute Australia, University of Sydney, and Westmead Hospital (R.K.), Sydney, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Brisbane (V.A.), and Alfred Hospital, Melbourne, VIC (A. Haydon) - all in Australia; University Hospital Schleswig-Holstein, Kiel (A. Hauschild), and University Hospital Essen, Essen, and the German Cancer Consortium, Heidelberg (D.S.) - all in Germany; Fondazione Istituto Nazionale Tumori, Milan (M.S.), Papa Giovanni XXIII Cancer Center Hospital, Bergamo (M.M.), and the Melanoma Oncology Unit, Veneto Oncology Institute, Padua (V.C.-S.) - all in Italy; Rikshospitalet-Radiumhospitalet, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux (C.D.), Institute Gustave Roussy, Paris (C.R.), Université de Lille, INSERM Unité 1189, Centre Hospitalier Régional Universitaire de Lille, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; Ella Institute for Melanoma, Sheba Medical Center, Tel Hashomer, Israel (J.S.); Royal Marsden NHS Foundation Trust, London (J. Larkin), and Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne (R.P.) - both in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (R.J., P.Z., B.M., J. Legos); University Hospital Zürich Skin Cancer Center, Zurich, Switzerland (R.D.); and the Melanoma Program, Hillman UPMC Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1708539
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1708539DOI Listing
November 2017

Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.

Br J Cancer 2017 Sep 8;117(7):1026-1035. Epub 2017 Aug 8.

Victorian Melanoma Service, Alfred Hospital, Melbourne, Victoria 3004, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.254DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625668PMC
September 2017

Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy.

Br J Cancer 2017 Sep 10;117(7):921-924. Epub 2017 Aug 10.

Department of Medical Oncology, Alfred Health, Melbourne, Victoria 3004, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.253DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625667PMC
September 2017

Student life - Where are all the male nursing students?

Authors:
Andrew Haydon

Nurs Stand 2017 Apr;31(33):35

University of West London.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7748/ns.31.33.35.s41DOI Listing
April 2017

Metastatic pathways in patients with cutaneous melanoma.

Pigment Cell Melanoma Res 2017 01 30;30(1):13-27. Epub 2016 Nov 30.

Victorian Melanoma Service, Alfred Hospital, Melbourne, Vic, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12544DOI Listing
January 2017

The Victorian Melanoma Service: A 20-year review of an Australian multidisciplinary cancer service.

Australas J Dermatol 2016 Aug 12;57(3):235-7. Epub 2015 Nov 12.

Victorian Melanoma Service, Alfred Hospital, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajd.12413DOI Listing
August 2016

A Randomized Controlled Trial of a Nurse-Led Supportive Care Package (SurvivorCare) for Survivors of Colorectal Cancer.

Oncologist 2016 08 15;21(8):1014-23. Epub 2016 Jun 15.

Department of Cancer Experiences Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia Department of Psychology, Swinburne University of Technology, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0533DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978555PMC
August 2016

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.

J Clin Oncol 2016 07 25;34(19):2258-64. Epub 2016 Apr 25.

Eva Segelov, St Vincent's Clinical School, University of New South Wales; Subotheni Thavaneswaran, Kristy P. Robledo, Val J. Gebski, Mustafa Khasraw, Kate Wilson, and John Simes, National Health and Medical Research Council Clinical Trials Centre (NHMRC), University of Sydney; Lorraine A. Chantrill, Macarthur Cancer Therapy Centre, Campbelltown Hospital and Kinghorn Cancer Centre; Nick Pavlakis and Mustafa Khasraw, Royal North Shore Hospital University of Sydney, Sydney; Paul M. Waring and Sebastian Lunke, Centre for Translational Pathology, University of Melbourne; Jayesh Desai, Royal Melbourne Hospital; Jayesh Desai and Michael Jefford, Peter MacCallum Cancer Centre; Andrew Haydon, Alfred Hospital; Jeremy D. Shapiro, Cabrini Hospital, Melbourne; Louise M. Nott, Royal Hobart Hospital, Hobart; Christos S. Karapetis, Flinders University and Flinders Medical Centre; Timothy J. Price, Queen Elizabeth Hospital and Lyell McEwin Hospital, Adelaide; Craig Underhill, Border Medical Oncology, Albury-Wodonga; Guy van Hazel, Sir Charles Gairdner Hospital, Perth, Australia; Elena Elez, Vall d'Hebron University Hospital, Barcelona, Spain; Fortunato Ciardiello, Seconda Università degli Studi di Napoli, Naples, Italy; and Harpreet Wasan, Hammersmith Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.6843DOI Listing
July 2016

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.

Sci Transl Med 2016 07;8(346):346ra92

Division of Systems Biology and Personalised Medicine, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia. Department of Medical Oncology, Western Health, St Albans, Victoria 3021, Australia. Department of Medical Oncology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Victoria 3010, Australia. Ludwig Institute for Cancer Research, New York, NY 10017, USA.

View Article

Download full-text PDF

Source
http://stm.sciencemag.org/content/8/346/346ra92.full.pdf
Web Search
http://dx.doi.org/10.1126/scitranslmed.aaf6219DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346159PMC
July 2016

Complete Pathological Response After Neoadjuvant Long-Course Chemoradiotherapy for Rectal Cancer and Its Relationship to the Degree of T3 Mesorectal Invasion.

Dis Colon Rectum 2016 May;59(5):361-8

1 Cabrini Monash University Department of Surgery, Cabrini Hospital, Malvern, Victoria, Australia 2 Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Victoria, Australia 3 William Buckland Radiotherapy Centre, The Alfred Hospital, Department of Surgery, Monash University Central Clinical School, Melbourne, Victoria, Australia 4 Monash Department of Clinical Epidemiology, Cabrini Hospital, Malvern, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DCR.0000000000000564DOI Listing
May 2016

Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma.

Cancer Immunol Immunother 2015 Apr 7;64(4):507-18. Epub 2015 Feb 7.

Ludwig Institute for Cancer Research (Melbourne-Austin Branch), 147-163 Studley Road, Heidelberg, VIC, 3084, Australia,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-015-1656-xDOI Listing
April 2015

Prognosis associated with cutaneous melanoma metastases.

Australas J Dermatol 2015 Feb;56(1):25-8

Victorian Melanoma Service, The Alfred, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajd.12293DOI Listing
February 2015

Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype.

Mod Pathol 2013 Dec 28;26(12):1642-56. Epub 2013 Jun 28.

1] Cancer and Population Studies Group, Queensland Institute of Medical Research, Herston, QLD, Australia [2] Department of Histopathology, Sullivan Nicolaides Pathology, Taringa, QLD, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2013.101DOI Listing
December 2013

18F-fluorodeoxyglucose positron emission tomography-positive sarcoidosis after chemoradiotherapy for Hodgkin's disease: a case report.

J Med Case Rep 2011 Jun 29;5:247. Epub 2011 Jun 29.

Department of Nuclear Medicine, The Alfred Hospital, Commercial Road, Melbourne, Victoria 3004, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1752-1947-5-247DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150315PMC
June 2011

Investigation of the safety of irreversible electroporation in humans.

J Vasc Interv Radiol 2011 May 25;22(5):611-21. Epub 2011 Mar 25.

Department of Radiology, Alfred Hospital, Monash University, Melbourne, PO Box 315, Prahran, VIC 3181, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jvir.2010.12.014DOI Listing
May 2011

The effect of socioeconomic status on survival from colorectal cancer in the Melbourne Collaborative Cohort Study.

Soc Sci Med 2009 Jan 19;68(2):290-7. Epub 2008 Nov 19.

The Cancer Council Victoria, Carlton, Victoria 3053, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.socscimed.2008.09.070DOI Listing
January 2009

Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype.

Cancer Epidemiol Biomarkers Prev 2008 Jul;17(7):1774-80

Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, School of Population Health, The University of Melbourne, Level 1, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-08-0091DOI Listing
July 2008

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.

Invest New Drugs 2008 Feb 20;26(1):89-94. Epub 2007 Sep 20.

Cutaneous Oncology Program, University of Colorado Health Sciences Center, PO Box 6510, Mail Stop F703, Aurora, CO 80045, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-007-9080-5DOI Listing
February 2008

Body size and composition and risk of rectal cancer (Australia).

Cancer Causes Control 2006 Dec;17(10):1291-7

Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Carlton South, VIC, Australia.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10552-006-0074-y
Publisher Site
http://dx.doi.org/10.1007/s10552-006-0074-yDOI Listing
December 2006

Low somatic K-ras mutation frequency in colorectal cancer diagnosed under the age of 45 years.

Eur J Cancer 2006 Jul 9;42(10):1357-61. Epub 2006 Jun 9.

Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2006.02.023DOI Listing
July 2006

Body size and composition and colon cancer risk in women.

Int J Cancer 2006 Mar;118(6):1496-500

Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.21508DOI Listing
March 2006

Red meat, chicken, and fish consumption and risk of colorectal cancer.

Cancer Epidemiol Biomarkers Prev 2004 Sep;13(9):1509-14

Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
September 2004

Body size and composition and colon cancer risk in men.

Cancer Epidemiol Biomarkers Prev 2004 Apr;13(4):553-9

Cancer Epidemiology Centre, The Cancer Council Victoria, 1 Rathdowne Street, Carlton South, Melbourne, Victoria 3053, Australia.

View Article

Download full-text PDF

Source
April 2004

Emerging pathways in colorectal-cancer development.

Lancet Oncol 2002 Feb;3(2):83-8

Department of Epidemiology and Preventive Medicine, Monash Medical School, Alfred Hospital, Prahran, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1470-2045(02)00649-6DOI Listing
February 2002